Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Intrahepatic Cholangiocarcinoma: early-phase trial registry
13 of 18 indexed Intrahepatic Cholangiocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 13 currently recruiting · #953 of 28,707 conditions by registered trial count
Intrahepatic Cholangiocarcinoma: 18 US clinical trials tracked, 13 recruiting.
Intrahepatic Cholangiocarcinoma is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition intrahepatic-cholangiocarcinoma
OPEN 13 | RECR 72% | LATE 0 | EARLY 13 | RANK #953 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Cardiomyopathies (72% recruiting · 18 trials)
Intrahepatic Cholangiocarcinoma lists 13 open slots (72% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Intrahepatic Cholangiocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Intrahepatic Cholangiocarcinoma is recruiting above its size-band peers.
13 of 18 indexed trials (72.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Intrahepatic Cholangiocarcinoma research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 18 trials (16.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Intrahepatic Cholangiocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 18 trials that report a genuine target (sentinel values excluded). 11 of those (61.1%) plan for fewer than 100 participants.
-
Intrahepatic Cholangiocarcinoma research is mostly interventional.
16 interventional and 2 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
City of Hope Medical Center
NCT06342414
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
University of California, Davis
NCT06101277
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Alentis Therapeutics
NCT07169734
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04078230
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Memorial Sloan Kettering Cancer Center
NCT04891289
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Virogin Biotech Canada
NCT05223816
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
Michael J Cavnar, MD
NCT07201519
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Stanford University
NCT07223307
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Tyra Biosciences
NCT06160752
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Mehmet Akce
NCT06728410
Liver Transplantation in Intrahepatic Cholangiocarcinoma
Rutgers, The State University of New Jersey
NCT06140134
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Inova Health Care Services
NCT05422690
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
NCT05285358
Infusion System for Hepatic Cancer
Ronald DeMatteo, M.D.
NCT04684862
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Lisata Therapeutics
NCT05712356
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
NCT04526106
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Memorial Sloan Kettering Cancer Center
NCT01862315
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
NCT01938729
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Intrahepatic Cholangiocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Intrahepatic Cholangiocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Intrahepatic Cholangiocarcinoma page
18 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Intrahepatic Cholangiocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Intrahepatic Cholangiocarcinoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Intrahepatic Cholangiocarcinoma condition card totals 18 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.